Looking at sales growth by market compared to the prior year, core sales to the prescription market decreased 8%.
In pharma the increased demand for our injectable components including supplying some of the COVID-19 vaccine distributions, and increased demand for our active material science solution, including those for COVID-19 test kits, offset declines in the prescription drug and consumer healthcare markets.
Turning to our food and beverage segment, which had a solid performance, core sales increased 14% in the segment achieved adjusted EBITDA margin of 17% primarily due to the ongoing strength in the food market.
In closing, on slide eight, I'd like to mention that the broad range of end markets that we serve makes Aptar a very resilient company through economic cycles, and the most recent period was no exception.
We expect a second quarter adjusted earnings per share, excluding restructuring and any change in the fair value of equity investments to be in the range of $0.91 to $0.99 per share.
